![Luke Rosen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Luke Rosen is the founder of Kif1a Org.
Prior to founding Kif1a Org, he worked as Senior VP-Accelerated Development at Ovid Therapeutics, Inc. He received his undergraduate and graduate degrees from the University of Oxford.
| Sociétés | Poste | Fin |
|---|---|---|
Kif1a Org
 Kif1a Org Kif1a Org is a nonprofit organization dedicated to improving the lives of individuals and families affected by KIF1A Associated Neurological Disorder (KAND), a rare, progressive neurodegenerative genetic disease caused by mutations in the KIF1A gene. The non-profit company is based in Alexandria, VA. The organization focuses on accelerating research toward effective treatments and a cure, leading a worldwide collaborative research network involving over 50 institutions, including labs and biotech partners. Its initiatives include disease modeling, drug discovery, genetic studies, biomarker identification, and clinical characterization of KAND symptoms such as epilepsy, spasticity, and developmental delays. Kif1a Org runs a treatment accelerator program that uses patient-derived neurons to screen candidate therapeutics, manages patient registries and natural history studies, conducts specialized studies on epilepsy and speech impairments, and promotes brain donation programs. The organization provides resources for newly diagnosed families, community support, educational materials, and advocacy opportunities, emphasizing patient and family engagement in research and treatment development. The company was founded by Luke Rosen. | Fondateur | - |
| OVID THERAPEUTICS INC. | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 3 |
|---|---|
Ovid Therapeutics, Inc.
 Ovid Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Provides medicines to children and adults with neurological disorders | Health Technology |
University of Oxford
 University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Kif1a Org
Kif1a Org Kif1a Org is a nonprofit organization dedicated to improving the lives of individuals and families affected by KIF1A Associated Neurological Disorder (KAND), a rare, progressive neurodegenerative genetic disease caused by mutations in the KIF1A gene. The non-profit company is based in Alexandria, VA. The organization focuses on accelerating research toward effective treatments and a cure, leading a worldwide collaborative research network involving over 50 institutions, including labs and biotech partners. Its initiatives include disease modeling, drug discovery, genetic studies, biomarker identification, and clinical characterization of KAND symptoms such as epilepsy, spasticity, and developmental delays. Kif1a Org runs a treatment accelerator program that uses patient-derived neurons to screen candidate therapeutics, manages patient registries and natural history studies, conducts specialized studies on epilepsy and speech impairments, and promotes brain donation programs. The organization provides resources for newly diagnosed families, community support, educational materials, and advocacy opportunities, emphasizing patient and family engagement in research and treatment development. The company was founded by Luke Rosen. |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
